Indiana’s strategic advantage as a manufacturing powerhouse is dependent not just on companies that are building new plants with the latest technology but also in ensuring that existing manufacturers—many of which are suppliers for the big guys—implement the latest technology. If they don’t, they could lose the ability to compete.
Lilly plans to outfit its Lebanon plants—now under construction—with the latest in robotic, digital manufacturing equipment that will do much of the work that a generation ago was done by humans.
Eli Lilly and Co. plans to build the center on an existing parking lot at its downtown campus, with the goal of hosting more of its global meetings in Indianapolis.
The company said the site footprint will not expand, but the company will fill in the property with more buildings and equipment. Manufacturing capacity will almost triple there.
Lilly said the new investment will allow it to hire 200 more workers at the complex, including engineers, scientists, and lab technicians, for a total of 900 full-time workers when it is fully operational.
Hims can offer the prescription weight-loss drugs because U.S. regulators have rules that allow pharmacies to make copycat versions of drugs in shortage, a practice that’s known as “compounding.”
The roster of radiopharmaceuticals players in the Indianapolis area has surged in the past few years to include some of the world’s leading pharmaceutical companies, attracted by the potential for significant growth.
In a series of lawsuits Lilly filed in September and October in federal court, the drugmaker had accused Totality Medispa of trademark infringement, false advertising, unfair competition and unfair trade practices.
During its quarter century of existence, BCforward has become one of the nation’s largest Black-owned businesses, employing some 5,000 workers around the world.
The U.S. Food and Drug Administration is convening a panel of independent experts on June 10 to discuss donanemab’s safety and effectiveness, including the results in patients in a clinical trial.
IBJ talked with State Agriculture Director Don Lamb about the trade mission to Brazil, the importance of agriculture trade missions and Indiana’s import/export relationships.
A report issued Monday by BioCrossroads says Indiana life sciences companies saw a decrease in capital and investments last year, but made a significantly higher contribution to the state’s economy than they did the previous year.
Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.
The approval, the first step in the legislative process, came with nearly 100 Indy Eleven supporters packing a portion of the City-County Building Public Assembly Room to show their support for the team.
Lilly and the Fever said they would also use the partnership “to close gaps on health outcomes in Indianapolis and across the state” by raising awareness of health issues.
